Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A, Correas JM, Dorival C, Zoulim F, Tran A, Bourlière M, Calès P, Guyader D, Bronowicki JP, Larrey D, Hezode C, Loustaud-Ratti V, Gournay J, de Ledinghen V, Asselah T, Ganne N, Metivier S, Chazouillères O, Leroy V, Rosa I, Samuel D, Mathurin P, Cagnot C, Fontaine H, Carrat F, Pol S; AFEF ANRS study group.
Vallet-Pichard A, et al. Among authors: cales p.
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101459. doi: 10.1016/j.clinre.2020.04.022. Epub 2020 Jun 25.
Clin Res Hepatol Gastroenterol. 2021.
PMID: 32595103